AUGMEDIX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.2 USD | +3.45% |
|
+4.80% | -79.49% |
| May. 14 | Maxim Downgrades Augmedix to Hold From Buy | MT |
| May. 14 | B. Riley Adjusts Price Target on Augmedix to $3 From $5.50, Keeps Buy Rating | MT |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to Augmedix Inc.'s 2022 Fou...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Augmedix, Inc. helps clinicians and patients form a human connection at the point of care. The Company uses its proprietary Notebuilder Platform to automate the note creation process, aided by its trained MDSs. It also provides data services associated with these products, which include aggregated structured data and metadata associated with medical notes. Its products include Augmedix Live, Augmedix Notes, Augmedix Prep and Augmedix Go. Augmedix Live provides synchronous medical note documentation and point of care support. Augmedix Notes provides asynchronous medical documentation based upon previously recorded visit. Prep provides chart preparation delivered prior to the patient visit. Prep transfers patient demographics, past medical history, medication changes and other key data points from the patientâs health to the current visit note. Clinicians access its products and service through mobile devices, managed by it or their health enterprise.
Sector
Business Support Services
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.2
USD
Average target price
3.333
USD
Spread / Average Target
+177.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -79.49% | 56.54M | |
| +16.14% | 70.77B | |
| +6.93% | 17.14B | |
| +12.92% | 13.82B | |
| +19.72% | 13.49B | |
| +15.69% | 10.06B | |
| -18.67% | 7.24B | |
| -2.02% | 6.18B | |
| +3.92% | 5.26B | |
| +0.94% | 5.03B |
- Stock Market
- Equities
- AUGX Stock
- News Augmedix, Inc.
- Transcript : Augmedix, Inc., Q4 2022 Earnings Call, Mar 27, 2023